Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) reported that its HT-001 program met the primary efficacy endpoint in an interim analysis, with patients reaching an ARIGA ≤1 by week six. Over 65% of patients reported reduced pain and itching, with zero EGFR therapy disruptions and ~99% lower systemic exposure versus oral therapies. Hungary approved expansion of the Phase 2 trial into Europe, and site activations are expected soon in the U.S., Spain and Poland.
Positive
- Primary endpoint achieved: ARIGA ≤1 by week six
- Patient benefit: Over 65% reported reduced pain and itching
- No EGFR interruptions: Zero patients required dose reduction or discontinuation
- Low systemic exposure: ~99% lower systemic exposure versus oral therapies
- Regulatory expansion: Hungary approval to expand Phase 2 into Europe
Negative
- None.
News Market Reaction – HOTH
On the day this news was published, HOTH declined 34.86%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.8% during that session. Argus tracked a trough of -43.5% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $13.66M at that time. Trading volume was very high at 4.1x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HOTH gained 9.12% while key peers were mixed: PASG up 21.33%, QTTB up 8.81%, ELEV down 2.28%, CRIS slightly down. Only 1 peer (PASG) appeared on the momentum scanner, suggesting a stock-specific reaction to HT-001 data rather than a broad biotech move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Pipeline update | Positive | +5.3% | Company highlighted progress across HT-001, HT-KIT, HT-ALZ and new GDNF program. |
| Oct 21 | Orphan designation | Positive | +3.6% | FDA Orphan Drug Designation and strong preclinical data for HT-KIT in rare cancers. |
| Sep 10 | EMA submission | Positive | +10.3% | EMA submission to expand HT-001 Phase II trial in EGFRi-induced skin toxicities. |
| Sep 02 | Preclinical data | Positive | +10.3% | HT-KIT showed >80% KIT knockdown and rapid tumor shrinkage with strong bioanalytics. |
| Jul 29 | Trial expansion | Positive | -0.8% | Announced engagement with ICON and planned HT-001 Phase II expansion into Europe. |
Clinical and pipeline updates have generally produced positive moves, though one EU trial expansion headline saw a mild negative reaction.
Over the past year, Hoth’s clinical trial news has centered on HT-001 expansion into Europe and advancing HT-KIT through preclinical milestones. Prior updates included EMA and EU trial expansion steps for HT-001 and FDA Orphan Drug Designation plus potent anti-tumor activity for HT-KIT. These announcements often triggered single‑digit to low double‑digit price moves. Today’s interim Phase 2 HT-001 data and Hungary approval build directly on that European expansion and efficacy narrative.
Historical Comparison
Past clinical-trial headlines moved HOTH by an average of 5.74%. Today’s 9.12% gain on HT-001 interim efficacy and EU expansion sits above that but within the same general range.
HT-001 has progressed from EU trial planning and EMA submission toward broader Phase 2 execution, while HT-KIT advanced through potent preclinical data and Orphan Drug Designation, building a multi-asset clinical pipeline story.
Regulatory & Risk Context
The company has an effective Form S-3 mixed shelf filed on 2025-11-14, allowing primary offerings of up to $50 million in various securities plus resale of 1,279,587 shares, providing flexibility to raise capital via future prospectus supplements.
Market Pulse Summary
The stock dropped -34.9% in the session following this news. A negative reaction despite positive interim data would contrast with past clinical updates, which averaged moves of 5.74% on generally favorable news. Even with primary endpoint achievement and >65% of patients reporting symptom relief, investors must weigh financing needs, including a $50 million shelf registration, and broader biotech risk sentiment. Historical patterns show occasional divergence when expansion milestones did not immediately translate into sustained price strength.
Key Terms
pharmacokinetic (pk) medical
systemic exposure medical
AI-generated analysis. Not financial advice.
Over
In addition to the strong results in Ariga score, HT-001 demonstrated strong patient benefit across multiple clinically meaningful measures. Over
Importantly, zero patients required dose reduction or discontinuation of their EGFR inhibitor therapy while receiving HT-001, highlighting the potential for HT-001 to manage dermatologic side effects without interfering with life-saving cancer treatments.
HT-001 was also well tolerated, with no treatment discontinuations reported.
Pharmacokinetic (PK) analysis further demonstrated that HT-001 achieves approximately
Building on these positive results, Hoth has received regulatory approval in
"The achievement of these interim results, combined with strong patient-reported outcomes and the ability to maintain uninterrupted cancer therapy, represents a meaningful advancement for HT-001," said Robb Knie Chief Executive Officer of Hoth Therapeutics. "With over
Dermatologic toxicities remain a significant challenge for patients undergoing cancer treatment, often leading to discomfort, reduced quality of life, and in some cases treatment modification or discontinuation. HT-001's ability to demonstrate primary endpoint achievement, meaningful symptom improvement, and zero disruption to EGFR inhibitor therapy may represent a compelling advancement over existing treatment options.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hungary-approves-trial-expansion-as-ht-001-meets-primary-endpoint-in-interim-analysis-with-patients-reaching-ariga-1-by-week-six-302731156.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What interim results did HOTH announce for HT-001 on April 1, 2026?
How did HT-001 affect patients' EGFR cancer therapy continuity for HOTH?
What safety and exposure advantages did HOTH report for HT-001 compared to oral therapies?
What regulatory progress did HOTH report for expanding HT-001 Phase 2 on April 1, 2026?
How might HT-001's patient-reported outcomes impact HOTH's development timeline?
